population health

Research in Review

Risk-Adapted Therapy Recommended for Patients With Hodgkin Lymphoma

04/27/2017

JCP Editors

Long-term follow-up data from multiple studies support the current risk-adapted therapeutic strategies in early-stage Hodgkin lymphoma, according to research published in the Journal of Clinical Oncology (published...

...

04/27/2017

Journal of Clinical Pathways

Research in Review

New Prognostic Marker Identified for Diffuse Large B-Cell Lymphoma

04/27/2017

JCP Editors

A recent meta-analysis identified a strong correlation between an inflammation marker and survival outcomes for patients with diffuse large B-cell lymphoma, published in PLOS One (published online April 25, 2017;...

A...

04/27/2017

Journal of Clinical Pathways

Research in Review

Palbociclib Plus Fulvestrant Improves PFS in Type of Breast Cancer

04/19/2017

JCP Editors

Adding palbociclib to fulvestrant prolongs progression-free survival (PFS) compared with fulvestrant alone among pre- and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor...

Adding...

04/19/2017

Journal of Clinical Pathways

Research in Review

Maintenance Therapy Effective in Treating Diffuse Large B-Cell Lymphoma

04/12/2017

JCP Editors

Maintenance therapy with a targeting agent may provide survival benefits beyond first- and second-line chemotherapy in patients with diffuse large B-cell lymphoma, according to an analysis published in PLOS One...

...

04/12/2017

Journal of Clinical Pathways

Research in Review

Autologous Stem Cell Transplantation Improves Outcomes for Patients With MCL

04/11/2017

JCP Editors

Patients with mantle cell lymphoma (MCL) benefit from prolonged event-free survival (EFS) and overall survival (OS) when treated with autologous stem cell transplantation (ASCT) and total body irradiation, according...

...

04/11/2017

Journal of Clinical Pathways

Research Reports

Length of Stay and Costs of COPD: Analysis of Hospitalized Patients Treated With Arformoterol or Nebulized Short-Acting Beta2-Agonists

04/11/2017

Tina Hunter , PhD;

Scott B. Robinson , PhD, MD;

Vamsi K. Bollu , PhD, MBA;

Krithika Rajagopalan , PhD;

Bernadette H. Johnson , MBA;

Frank R. Ernst , PharmD, MS;

Abstract: Hospitalization costs are substantial in chronic obstructive pulmonary disease (COPD). Little is known regarding the effect of long-acting beta2-agonists (LABAs) vs short-acting beta2-agonists (SABAs) on...

...

04/11/2017

Journal of Clinical Pathways

Research in Review

Novel Therapy Plus Gemcitabine Does Not Improve OS in Pancreatic Cancer

04/11/2017

JCP Editors

A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to research...

A new...

04/11/2017

Journal of Clinical Pathways

Research in Review

New Drug Improves PFS for Patients With ALK-Positive NSCLC

04/10/2017

JCP Editors

Patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) live significantly longer without disease progression when treated with a new drug compared with those treated with...

...

04/10/2017

Journal of Clinical Pathways

Research in Review

B-Cell ALL Disease Burden May Influence CAR T-Cell Therapy Impact on Survival

04/10/2017

JCP Editors

CD19-specific chimeric antigen receptor (CAR) T-cell therapy is more likely to be effective when given immediately after front-line therapy rather than after relapse in certain patients with B-cell acute...

...

04/10/2017

Journal of Clinical Pathways

Research in Review

Rare Form of Colorectal Cancer Responds Well to Precision Medicine

04/06/2017

JCP Editors

Patients with a specific type of metastatic colorectal cancer who are chemotherapy-resistant benefit from treatment with a gene-targeting regimen. ----- Related Content ESMO announces changes to metastatic...

...

04/06/2017

Journal of Clinical Pathways